BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET

Rhea-AI Summary

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced that it will host a conference call and webcast on Monday, August 5, 2024, at 4:30 p.m. ET to discuss its second quarter 2024 financial results and provide a general business update. The call will be hosted by Alexander Hardy, President and Chief Executive Officer of BioMarin.

Participants can join the call using the following details:

• U.S. / Canada Dial-in: 888-596-4144
• International Dial-in: 646-968-2525
• Conference Call ID: 1816377

A live audio webcast will be available on the investor section of BioMarin's website, and a replay will be archived for one week following the call.

News Market Reaction

-1.03%

1 alert

-1.03% News Effect

On the day this news was published, BMRN declined 1.03%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN RAFAEL, Calif., July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 5, 2024, at 4:30 p.m. ET to discuss second quarter 2024 financial results and provide a general business update.

Dial-in Number
U.S. / Canada Dial-in Number: 888-596-4144
International Dial-in Number: 646-968-2525
Conference Call ID: 1816377

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1816377

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2024-financial-results-conference-call-and-webcast-on-monday-august-5-2024-at-430pm-et-302202972.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) report its Q2 2024 financial results?

BioMarin (BMRN) will report its Q2 2024 financial results on Monday, August 5, 2024, during a conference call and webcast scheduled for 4:30 p.m. ET.

Who will host BioMarin's (BMRN) Q2 2024 earnings call?

Alexander Hardy, President and Chief Executive Officer of BioMarin, will host the Q2 2024 earnings call and webcast.

How can investors access BioMarin's (BMRN) Q2 2024 earnings call?

Investors can access BioMarin's Q2 2024 earnings call by dialing 888-596-4144 (U.S./Canada) or 646-968-2525 (International) with Conference Call ID 1816377. A live audio webcast will also be available on BioMarin's investor website.

Will there be a replay available for BioMarin's (BMRN) Q2 2024 earnings call?

Yes, a replay of BioMarin's Q2 2024 earnings call will be archived on the company's investor website for one week following the call.